This information was published on 2021-11-29T09:15:42 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2230186 |
| (220) |
22 Nov 2021
|
| (300) |
US, 08 Jun 2021, 90780518
|
| (511) (510) |
Class 5
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer’s disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn’s disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson’s disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases. |
| (540) | KISUNLA |
| (550) | Word |
| (730) |
Eli Lilly and Company
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.